Author

N. Yoon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

A. Marusyk· 3 shared J. Scott· 2 shared R. Vander Velde· 2 shared A. C. Tan· 1 shared A. Dhawan· 1 shared A. Durmaz· 1 shared B. Desai· 1 shared B. J. Manley· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Marusyk

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Radio-Immune Response Modelling for Spatially Fractionated Radiotherapy

Y.-B. Cho, N. Yoon, J. H. Suh, S. G. Jacob

This study models the immune response in spatially fractionated radiotherapy, showing how heterogeneous dose distributions affect tumor cell killing through immune mechanisms.

bioRxiv · Apr 28, 2023Cancer Biology

Modeling collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy

N. Yoon, N. P. Krishnan, J. G. Scott

The paper develops a dynamical model for optimal sequential drug therapies with collaterally sensitive drugs and shows that shaping tumor heterogeneity followed by drug switching maintains subpopulations effectively.

bioRxiv · Jul 2, 2020 · PreprintCancer Biology

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

R. Vander Velde, N. Yoon, V. Marusyk, A. Durmaz, A. Dhawan, D. Myroshnychenko, D. Peral, B. Desai, O. Balynska, J. Poleszhuk, K. Liu, M. Abazeed, A. C. Tan, O. Mian, E. Haura, , A. Marusyk

The paper investigates resistance to ALK inhibitors in NSCLC, finding that resistance develops through gradual, multifactorial genetic and epigenetic changes rather than single mutations or reprogramming.

bioRxiv · Nov 19, 2019Cancer Biology

The impact of tumor stromal architecture on therapy response and clinical progression

P. Altrock, N. Yoon, J. A. Bull, H. Wu, J. Ruiz-Ramirez, D. Miroshnychenko, G. J. Kimmel, E. Kim, R. J. Vander Velde, K. Rejniak, B. J. Manley, F. Spill, A. Marusyk

This paper investigates how tumor stromal architecture influences therapy response and resistance in lung, breast, and kidney cancers using mathematical models, experimental studies, and clinical analysis.

bioRxiv · Oct 24, 2018 · PreprintCancer Biology

Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs

N. Yoon, R. Vander Velde, A. Marusyk, J. Scott

This paper develops a dynamical model to determine optimal drug switching schedules for collaterally sensitive drugs in cancer treatment, finding that the initial drug phase should be shorter than its effective duration.

bioRxiv · Feb 20, 2018Cancer Biology